Rocco Serrao, MD, Dermatologist, Mason, Ohio; roflumilast clinical trial investigator
Lawrence Eichenfield, MD; and Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis
A pair of roflumilast clinical trial investigators react to the FDA approval of the 0.05% formulation to treat atopic dermatitis in children 2 to 5 years.